Somatic Systems, Inc. (SMAS)

Somatic Systems, Inc. (SMAS) — VMCI valuation read

SMAS screens at VMCI 25/100, a 25-point gap below the Healthcare sector median (50). For a mid-cap Somatic Systems, Inc. share, that placement says the multi-pillar composite is richer or lower quality than the typical peer on a like-for-like basis.

SMAS has logged no Form 4 insider activity over the trailing 30 days. The tape reads neither bullish nor bearish on insider conviction. The next signal sits with the 10-Q schedule and the analyst calendar.

**Investor frame.** Value: SMAS trades at 20.0x earnings, 11% above the Healthcare median of 18.0x, while EV/EBITDA prints 9.0x against 12.0x for the Healthcare group. Quality: ROIC of 16.0% sits 6.0pp above the Healthcare median (10.0%), the cleanest like-for-like comparison on capital efficiency. Risk: net debt to EBITDA of 3.2x is the binding constraint on the bear case, which sets the rate-cycle exposure for Somatic Systems, Inc..

SMAS fell 2.0% over the trailing 7 days, with a -23.9% read on a 30-day basis.